Beta blockers and their appropriate use in patients with dyslipidemia

Authors

  • Marleni Hernández Parets
  • Zoila Armada Esmore
  • Lisset Jiménez Fernández
  • Estrella M. Hernández Hurtado

Abstract

Beta blockers and their appropriate use in patients with dyslipidemia

Downloads

Download data is not yet available.

References

1. Oates JA, Brown NJ. Antihipertensores y fármaco-terapia de hipertensión. En: Hardman JG, Limbird LE. Goodman Gilman: las Bases farmacológicas de la terapéutica. 10ma ed. México: McGraw Hil; 2003. p. 881-910.

2. Yodú Ferral N. Fármacos que actúan sobre el siste-ma cardiovascular. Hipertensión arterial. En: Morón Rodríguez FJ, Borroto Regalado R, Calvo Barbado DM, Cires Pujol M, Cruz Barrios MA, Fernández García A, et al. Farmacología clínica. La Habana: ECIMED; 2010. p. 1-34.

3. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, et al. Effects of me-toprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or metoprolol European Trial (COMET). Heart. 2007;93:8968-73.

4. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24(7): 1397-403.

5. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evalua-tion, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.

6. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects

of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. The Lancet. 2010;375(9718):906-15.

7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.

8. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of euro-pean guidelines on hypertension management: a European Society of Hypertension Task Force docu-ment. J Hypertens. 2009;27(11):2121-58.

9. Shrivastava A, Gupta VB. Stability-Indicating RP-HPLC Method for the simultaneous determination of Prazosin, Terazosin, and Doxazosin in pharma-ceutical formulations. Sci Pharm. 2012;80(3):619-31.

10.De Backer G, Ambrosioni E, Borch-Johnsen K, Bro-tons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease pre-vention in clinical practice. European guidelines on cardiovascular disease prevention in clinical prac-tice. Eur J Cardio Prev Rev. 2003;10(4):S1-S10.

11.Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR, et al. Baseline heart rate, antihy-pertensive treatment, and prevention of cardio-vascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009; 54(13):1154-61.

12.Lavie CJ, Messerli FH, Milani RV. Beta-blockers as first-line antihypertensive therapy. The crumbling continues. J Am Coll Cardiol. 2009;54(13):1162-4.

13.Actualización en el tratamiento de la hipertensión arterial. BOLCAN [Internet]. 2011 [citado 5 Ene 2012];3(3):[aprox. 8 p.]. Disponible en:

http://www2.gobiernodecanarias.org/sanidad/scs/content/ee6b9302-a3cf-11e0-9610-f1717f4d08a3/bolcan_HTA_11.pdf

14.Los antagonistas de los receptores de angiotensina II (ARA-II) en el manejo de los pacientes hiperten-sos [Internet]. Santa Fe: Medicinapreventiva. Dis-ponible en:

http://www.medicinapreventiva.com.ve/articulos/antagonistas_de_los_receptores_de_angiotensina_II.htm

15.O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, DickerP, et al. Aliskiren reduces blood

pressure and suppresses plasma renin activity in combination with a thiazide diuretic, anangioten-sin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49(2):276-84.

Downloads

Published

2013-07-12

How to Cite

1.
Hernández Parets M, Armada Esmore Z, Jiménez Fernández L, Hernández Hurtado EM. Beta blockers and their appropriate use in patients with dyslipidemia. CorSalud [Internet]. 2013 Jul. 12 [cited 2025 Jun. 22];5(3):311-4. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/540

Issue

Vol. 5 No. 3 (2013)

Section

LETTERS TO THE EDITOR

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.